Clinical Evaluation of the RH210 Hearing Aid

Clinical Evaluation of the RH210 Hearing Aid Software Used With RH210A Device in Adults With Perceived Mild-to-Moderate Hearing Loss

The RH210A is an air-conduction hearing aid designed for adults with perceived mild-to-moderate sensorineural hearing loss. The purpose of this clinical investigation is to generate objective and subjective evidence of the clinical performance and safety of the device.

Study Overview

• Status: Recruiting
• Conditions: Hearing Impairment, Sensorineural; Perceived Hearing Loss
• Intervention / Treatment: Device: Investigational device (RH210A); Device: Apple AirPods Pro (2nd Generation) with Hearing Aid Feature (HAF)

Detailed Description

The primary objective of this clinical investigation is to demonstrate that the RH210A device provides a clinically meaningful improvement in speech understanding in noise compared with unaided listening in adults with perceived mild-to-moderate hearing loss.

Speech-in-noise performance will be assessed using the BKB-SIN (Australian version), which quantifies the change in signal-to-noise ratio required for sentence recognition. The primary endpoint is defined as the within-subject difference between unaided and RH210 conditions (change in SNR = Unaided - RH210). A successful outcome is defined as a mean improvement of equal to or more than 2 dB in SNR with RH210 compared to unaided listening.

• Study Type: Interventional
• Enrollment (Estimated): 24
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Marisa Poulos, Master of Audiology; Phone Number: +61 2 9412 6872; Email: marisa.poulos@nal.gov.au
• Study Contact Backup: Name: Sanna Hou, Master of Audiology; Phone Number: +61 2 9412 6872; Email: sann.hou@nal.gov.au

Study Locations

• Australia
  • New South Wales
    • Macquarie Park, New South Wales, Australia
      • Recruiting
      • National Acoustic Laboratories
      • Contact: Bettina Turnbull, AuD; Email: Bettina.Turnbull@nal.gov.au
      • Principal Investigator: Bettina Turnbull, AuD

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Age 18 years
• Self-perceived mild-to-moderate hearing difficulties/ hearing loss
• Competent smartphone use (able to complete self-fitting via the app)
• Able and willing to provide informed consent
• HHIA screening consistent with perceived hearing difficulty
• Willingness and ability to attend two in-person research appointments
• Ability to operate a SmartPhone

Exclusion Criteria:

• Conductive or mixed hearing loss
• Occluding cerumen
• Otologic disease/ active ear pathology
• Severe or profound hearing loss (PTA >S0dBHL) (WHO, 2021)
• Presence of (red-flag) conditions relevant to OTC hearing aid use (per 21 CFR 801.421)
• Visible deformity of the ear (congenital or traumatic).
• Fluid, pus, or blood coming from the ear (e.g., active drainage).
• Sudden or rapidly progressive hearing loss within the recent past (often defined as within ~90 days).
• Any acute or chronic dizziness or vertigo associated with hearing issues.
• Pain or discomfort in or around the ear.
• Visible evidence of significant cerumen (ear wax) accumulation or foreign body in the ear canal.
• Unilateral hearing loss of sudden onset or large asymmetry between ears.
• Audiometric air-bone gap suggestive of possible conductive pathology (e.g., gap equal or more than 15 dB at key frequencies)
• Visible evidence of significant cerumen (ear wax) accumulation or foreign body in the ear canal.
• Unilateral hearing loss of sudden onset or large asymmetry between ears

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Non-Randomized
• Interventional Model: Crossover Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Other: All participants; Trial device assessment in first appointment, comparator in second appointment	Device: Investigational device (RH210A); Over the counter device; Device: Apple AirPods Pro (2nd Generation) with Hearing Aid Feature (HAF); FDA cleared OTC device (Control arm)
Other: All Participants; Comparator in appointment one, trial device in appointment 2	Device: Investigational device (RH210A); Over the counter device; Device: Apple AirPods Pro (2nd Generation) with Hearing Aid Feature (HAF); FDA cleared OTC device (Control arm)

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Aided vs unaided pure-tone audiogram (PTA) measured in dBSPL	Aided audiogram with both the investigational and control device measured at 500, 1000, 2000 and 4000Hz in dBSPL. Compared with unaided audiogram measured at the same frequencies in dBSPL. Measured conducted in the sound field in a sound isolated room with warble tones presented from 0 degrees azimuth.	Day 1 (Visit 1) and Day 7 (Visit 2)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Speech understanding in background noise (BKB-SIN; AUS)	Participants will be asked to perform a speech in noise test. Participants will be presented with speech sentences and asked to recall the words they hear. The target stimuli will comprise of BKB sentences (Australian English version), and the noise will be spatially diffuse speech babble. The noise level will be fixed and the speech level will be adaptively changed (Keidser et al, 2013) to determine the speech reception threshold at 50% in dB SNR recall performance, using phonemic scoring. The test conditions, unaided and aided, will comprise of four repeated measures each, with 32 sentence repeats, conducted at 50% threshold. The order of conditions will be randomized across participant. The device will be set to 'Immersive Conversation' mode. For the AirPods Pro 2, the Hearing Aid setting will be toggled, and the AirPods set in Transparency mode.	Day 1 (Visit 1) and Day 7 (Visit 2)
Real Ear Measure Measurement (REIG)	Measurement of the Real Ear Insertion Gain (REIG) for the control and intervention device. Output will be compared with the prescribed NAL-R target values.	Day 1 (Visit 1) and Day 7 (Visit 2)
Moderated walk to evaluate simulated "real world benefit" (Ecological Momentary Assessment (EMA): NAL Australia).	Participants will use the to use the devices in a controlled, moderated, 60 minute walk. The walk will cover five key listening environments and : Library (~40 dBA) very low or no noise; Office (~50 dBA) with low level noise; Outdoor parkway (~55 dBA) with environmental noise; Traffic / street (~70-75 dBA) with traffic noise; Café / food court (~65-70 dBA) with multi-talker babble noise Performance will be evaluated using the Ecological Momentary Assessment (EMA) (NAL Australia). The study participants will provide feedback by selecting a rating on a five-point Likert scale for questions related to subjective impressions for speech intelligibility, listening effort, loudness/comfort and their aided/unaided preference while using the trial device or control device during the moderated walk.	Day 1 (Visit 1) and Day 7 (Visit 2)

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Usability of RH210 using the System Usability Survey (SUS: NAL)	Assess the subjective usability of the RH210 hearing aid software and application workflow in real-world use using the System Usability Survey (SUS) from the National Acoustic Laboratory (NAL). This is to gather data for a proposed human factors evaluation. The scoring is; Poor: Scores below 51 are considered poor.; Average Score: 68.; Above Average: > 68.; Below Average: < 68.; Good/Excellent: Scores over 79 are considered good, while 80.3 or higher is an A grade.	Day 1 (Visit 1) and Day 7 (Visit 2)

Collaborators and Investigators

• Sponsor: Rehear Audiology Company LTD
• Collaborators: Global Edge Medtech Consulting; National Acoustic Laboratories
• Investigators: Principal Investigator: Bettina Turnbull, Doctor of Audiology, National Acoustic Laboratories

Study record dates

Study Major Dates

• Study Start (Actual): April 11, 2026
• Primary Completion (Estimated): July 30, 2026
• Study Completion (Estimated): August 30, 2026

Study Registration Dates

• First Submitted: April 16, 2026
• First Submitted That Met QC Criteria: April 30, 2026
• First Posted (Actual): May 7, 2026

Study Record Updates

• Last Update Posted (Actual): May 29, 2026
• Last Update Submitted That Met QC Criteria: May 26, 2026
• Last Verified: April 1, 2026

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Neurologic Manifestations; Nervous System Diseases; Otorhinolaryngologic Diseases; Sensation Disorders; Ear Diseases; Hearing Loss; Hearing Disorders; Pathological Conditions, Signs and Symptoms; Signs and Symptoms; Hearing Loss, Sensorineural
• Other Study ID Numbers: NAL C26.02

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO
• IPD Plan Description: The study is a commercial sponsor investigation of a product that is not yet cleared by regulatory.

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No